Skip to main content
. 2022 Mar 21;11(3):170–185. doi: 10.4103/EUS-D-21-00044

Figure 2.

Figure 2

Forest plot showing pooled rates of adverse events (a) and pancreatitis (b) after EUS–radiofrequency ablation and EUS-EA of pancreatic neuroendocrine tumors